Comparing Bluejay Diagnostics (NASDAQ:BJDX) and Fresenius SE & Co. KGaA (OTCMKTS:FSNUY)
Comparing Bluejay Diagnostics (NASDAQ:BJDX) and Fresenius SE & Co. KGaA (OTCMKTS:FSNUY)
Bluejay Diagnostics (NASDAQ:BJDX – Get Rating) and Fresenius SE & Co. KGaA (OTCMKTS:FSNUY – Get Rating) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
BlueJay Diagnostics(納斯達克代碼：BJDX-GET Rating)和Fresenius SE&Co.KGaA(場外交易市場代碼：FSNUY-GET Rating)都是醫療公司，但哪項業務更優越？我們將根據這兩家公司的分析師建議、估值、風險、機構所有權、股息、盈利能力和收益的強弱對它們進行比較。
Earnings & Valuation
收益與估值
This table compares Bluejay Diagnostics and Fresenius SE & Co. KGaA's revenue, earnings per share and valuation.
下表比較了Bluejay Diagnostics和Fresenius SE&Co.KGaA的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bluejay Diagnostics | N/A | N/A | -$3.49 million | ($0.44) | -1.61 |
| Fresenius SE & Co. KGaA | $44.39 billion | 0.32 | $2.15 billion | $0.82 | 7.73 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| BlueJay診斷 | 不適用 | 不適用 | -349萬元 | ($0.44) | -1.61 |
| 費森尤斯SE&Co.KGaA | 443.9億美元 | 0.32 | 21.5億美元 | $0.82 | 7.73 |
Fresenius SE & Co. KGaA has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Fresenius SE & Co. KGaA, indicating that it is currently the more affordable of the two stocks.
費森尤斯SE&Co.KGaA的收入和收益高於Bluejay Diagnostics。BlueJay Diagnostics的市盈率低於Fresenius SE&Co.KGaA，這表明它目前是兩隻股票中更負擔得起的一隻。
Insider & Institutional Ownership
內部人與機構所有權
Analyst Ratings
分析師評級
This is a breakdown of current ratings and price targets for Bluejay Diagnostics and Fresenius SE & Co. KGaA, as reported by MarketBeat.com.
據MarketBeat.com報道，這是Bluejay Diagnostics和Fresenius SE&Co.KGaA目前的評級和目標價細分。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bluejay Diagnostics | 0 | 0 | 1 | 0 | 3.00 |
| Fresenius SE & Co. KGaA | 0 | 5 | 4 | 0 | 2.44 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| BlueJay診斷 | 0 | 0 | 1 | 0 | 3.00 |
| 費森尤斯SE&Co.KGaA | 0 | 5 | 4 | 0 | 2.44 |
Bluejay Diagnostics presently has a consensus target price of $10.00, indicating a potential upside of 1,308.45%. Fresenius SE & Co. KGaA has a consensus target price of $39.34, indicating a potential upside of 520.55%. Given Bluejay Diagnostics' stronger consensus rating and higher probable upside, equities analysts plainly believe Bluejay Diagnostics is more favorable than Fresenius SE & Co. KGaA.
BlueJay Diagnostics目前的共識目標價為10.00美元，表明潛在上行空間為1,308.45%。Fresenius SE&Co.KGaA的一致目標價為39.34美元，顯示潛在上行520.55%。鑑於Bluejay Diagnostics的普遍評級更高，上行可能性也更高，股票分析師顯然認為Bluejay Diagnostics比Fresenius SE&Co.KGaA更有利。
Profitability
盈利能力
This table compares Bluejay Diagnostics and Fresenius SE & Co. KGaA's net margins, return on equity and return on assets.
下表比較了Bluejay Diagnostics和Fresenius SE&Co.KGaA的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| Bluejay Diagnostics | N/A | -47.07% | -43.59% |
| Fresenius SE & Co. KGaA | 4.17% | 5.58% | 2.32% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| BlueJay診斷 | 不適用 | -47.07% | -43.59% |
| 費森尤斯SE&Co.KGaA | 4.17% | 5.58% | 2.32% |
Summary
摘要
Fresenius SE & Co. KGaA beats Bluejay Diagnostics on 8 of the 12 factors compared between the two stocks.
費森尤斯SE&Co.KGaA在比較兩隻股票的12個因素中有8個超過了Bluejay Diagnostics。
About Bluejay Diagnostics
關於Bluejay診斷公司
(Get Rating)
(獲取評級)
Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
BlueJay診斷公司是一家診斷公司，在美國開發和銷售用於分診、診斷和監測疾病進展的患者產品。它正在開發一個技術平臺，包括使用非接觸式離心力協調血液處理、生物標記物分離和免疫分析準備的SYMPHONY熒光免疫分析儀；以及包括試劑和組件的SYMPHONY卡片庫。該公司還提供AlLEREYE診斷測試，這是一種用於診斷過敏性結膜炎的POC設備。此外，它還開發用於檢測其他疾病的生物標記物，例如用於心肌損傷的hsTnT/I和用於心力衰竭的NT-proBNP。它與東麗工業公司簽訂了製造和分銷蛋白質檢測芯片的許可和供應協議。BlueJay Diagnostics，Inc.成立於2015年，總部位於馬薩諸塞州阿克頓。
About Fresenius SE & Co. KGaA
關於Fresenius SE&Co.KGaA
(Get Rating)
(獲取評級)
Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.
Fresenius SE&Co.KGaA是一家醫療保健公司，為透析、醫院和門診醫療提供產品和服務。它通過四個部門運作：費森尤斯醫療保健、費森尤斯·卡比、費森尤斯·赫利奧斯和費森尤斯·瓦米德。費森尤斯醫療保健部門為慢性腎功能衰竭患者提供產品和服務。這一細分市場提供透析器、血液透析機和相關一次性產品，以及與透析相關的服務。Fresenius Kabi部門從事治療和護理患病患者的治療和護理。這一領域提供四種藥物，包括用於腫瘤、麻醉劑、止痛劑、抗感染和重症護理的靜脈給藥的仿製藥；腸外和腸內營養產品；用於輸液治療的輸液和血容量替代品；生物仿製藥，一種治療自身免疫和腫瘤疾病的生物藥物；用於管理四種非專利藥物、輸液療法和臨牀營養產品的醫療器械和處置；以及用於採集血液成分和身體療法的輸血產品。費森尤斯·赫利奧斯分部在德國經營着90家醫院、大約130家門診診所和6個預防中心；在西班牙經營着49家醫院、88家門診診所和大約300個風險預防中心。這一部分還通過33個診所和另外39個地點，在3大洲10個國家提供不孕症治療服務。費森尤斯·瓦米德部門管理項目，併為醫院和其他衞生保健設施提供服務。這一部分提供項目開發、規劃和交鑰匙建設服務，以及維護和技術管理, 和運營管理服務。該公司前身為Fresenius SE，並於2011年1月更名為Fresenius SE&Co.KGaA。Fresenius SE&Co.KGaA成立於1912年，總部設在德國巴德洪堡Vor der HöHe。
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
接收Bluejay診斷日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收Bluejay Diagnostics和相關公司的最新新聞和分析師評級的每日摘要。